Skip Navigation


Carcinogenesis Advance Access originally published online on June 5, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
24/8/1389    most recent
bgg079v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kinoshita, A.
Right arrow Articles by Fukushima, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kinoshita, A.
Right arrow Articles by Fukushima, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol. 24, No. 8, 1389-1399, August 2003
© 2003 Oxford University Press


CARCINOGENESIS

Phenobarbital at low dose exerts hormesis in rat hepatocarcinogenesis by reducing oxidative DNA damage, altering cell proliferation, apoptosis and gene expression

Anna Kinoshita1, Hideki Wanibuchi1, Keiichirou Morimura1, Min Wei1, Jun Shen1, Susumu Imaoka2,3, Yoshihiko Funae2 and Shoji Fukushima1,4

1 Department of Pathology, Osaka City University Medical School, Abeno-ku, Asahi-machi 1-4-3, Osaka 545-8585, Japan
2 Department of Chemical Biology, Osaka City University Medical School, Abeno-ku, Asahi-machi 1-4-3, Osaka 545-8585, Japan

4 To whom correspondence should be addressed Email: fukuchan{at}med.osaka-cu.ac.jp

Our recent research indicated that phenobarbital (PB) may inhibit the development of N-diethylnitrosamine (DEN)-initiated pre-neoplastic lesions at low doses in a rat liver medium-term bioassay (Ito test), while high doses exhibit promoting activity. This raises the question of whether treatment with low doses of PB might reduce cancer risk. For clarification, male 6-week-old F344 rats were treated with PB at doses of 0, 2, 15 and 500 p.p.m. in the diet for 10 or 33 weeks after initiation of hepatocarcinogenesis with DEN. In a second, short-term experiment, animals were given PB at doses of 2, 4, 15, 60 and 500 p.p.m. for 8 days. Formation of glutathione S-transferase placental form (GST-P) positive foci and liver tumors was inhibited at 2 p.p.m. Generation of oxidative DNA damage marker, 8-hydroxy-2'-deoxyguanosine (8-OHdG), cellular proliferation within the areas of GST-P positive foci and apoptosis in background liver parenchyma were suppressed. Suppression of 8-OHdG formation by PB at low dose might be related to the enhanced mRNA expression of 8-OHdG repair enzyme, oxoguanine glycosylase 1 (Ogg1). Moreover, as detected by cDNA microarray analysis, PB treatment at low dose enhanced mRNA expression of glutamic acid decarboxylase (GAD65), an enzyme involved in the synthesis of gamma-aminobutyric acid (GABA), and suppressed MAP kinase p38 and other intracellular kinases gene expression. On the contrary, when PB was applied at a high dose, GST-P positive foci numbers and areas, tumor multiplicity, hydroxyl radicals and 8-OHdG levels were greatly elevated with the increase in CYP2B1/2 and CYP3A2 mRNA, protein, activity and gene expression of GST, nuclear tyrosine phosphatase, NADPH- cytochrome P-450 reductase and guanine nucleotide binding protein G(O) alpha subunit. These results indicate that PB exhibits hormetic effect on rat hepatocarcinogenesis initiated with DEN by differentially altering cell proliferation, apoptosis and oxidative DNA damage at high and low doses.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Physiol. GenomicsHome page
N. Aluru and M. M. Vijayan
Hepatic transcriptome response to glucocorticoid receptor activation in rainbow trout
Physiol Genomics, November 14, 2007; 31(3): 483 - 491.
[Abstract] [Full Text] [PDF]


Home page
Evid Based Complement Alternat MedHome page
N. Bhattacharjee, S. Pathak, and A. R. Khuda-Bukhsh
Amelioration of Carcinogen-Induced Toxicity in Mice by Administration of a Potentized Homeopathic Drug, Natrum Sulphuricum 200
Evid. Based Complement. Altern. Med., June 19, 2007; (2007) nem067v1.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
M. Moto, M. Okamura, M. Muguruma, T. Ito, M. Jin, Y. Kashida, and K. Mitsumori
Gene Expression Analysis on the Dicyclanil-Induced Hepatocellular Tumors in Mice
Toxicol Pathol, October 1, 2006; 34(6): 744 - 751.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
M. Nishikawa-Ogawa, H. Wanibuchi, K. Morimura, A. Kinoshita, T. Nishikawa, S. Hayashi, Y. Yano, and S. Fukushima
N-acetylcysteine and S-methylcysteine inhibit MeIQx rat hepatocarcinogenesis in the post-initiation stage
Carcinogenesis, May 1, 2006; 27(5): 982 - 988.
[Abstract] [Full Text] [PDF]


Home page
MutagenesisHome page
N. Asano, D. K. Torous, C. R. Tometsko, S. D. Dertinger, T. Morita, and M. Hayashi
Practical threshold for micronucleated reticulocyte induction observed for low doses of mitomycin C, Ara-C and colchicine
Mutagenesis, January 1, 2006; 21(1): 15 - 20.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
S. Fukushima, A. Kinoshita, R. Puatanachokchai, M. Kushida, H. Wanibuchi, and K. Morimura
Hormesis and dose-response-mediated mechanisms in carcinogenesis: evidence for a threshold in carcinogenicity of non-genotoxic carcinogens
Carcinogenesis, November 1, 2005; 26(11): 1835 - 1845.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.